ATR and gastric cancer: In conclusion, it is evident that the PAK6 is not only a stable biomarker to identify the chemoresistance to oxaliplatin in GC, but is also an important HR repair factor that demonstrated a novel function in activating ATR/CHK1 signaling to regulate HR repair.